GLP-1 Weight Loss in Arizona: How to Choose a Program

GLP-1 medications have changed what is possible for weight and metabolic health. The harder question is not whether they work. It is whether the program around the prescription keeps you safe, protects your muscle, and plans for what comes next.

This guide covers the research, where compounded GLP-1s stand in 2026, and what a GLP-1 program in Scottsdale, Phoenix, or anywhere in Arizona should include. For why weight shifts in midlife, see GLP-1s and midlife weight gain.

Which GLP-1 weight loss medications are FDA-approved in 2026?

The main GLP-1-based medications FDA-approved for chronic weight management in adults are Wegovy injection, the Wegovy pill, Zepbound, and Foundayo. Saxenda (liraglutide), an older daily injection, is also approved. Ozempic and Mounjaro contain the same active ingredients as Wegovy and Zepbound but are approved for type 2 diabetes, not weight management.

According to the National Institute of Diabetes and Digestive and Kidney Diseases, these medications are generally prescribed for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure or type 2 diabetes.

Medication	Active ingredient	Form	Key trial result
Wegovy	Semaglutide 2.4 mg	Weekly injection	14.9% average loss at 68 weeks (STEP 1)
Wegovy pill	Oral semaglutide 25 mg	Daily tablet	13.6% vs 2.4% placebo, all participants (OASIS 4)
Zepbound	Tirzepatide	Weekly injection	Up to 20.9% average loss at 72 weeks (SURMOUNT-1)
Foundayo	Orforglipron	Daily tablet	12.4% vs 0.9% placebo at highest dose, 72 weeks (ATTAIN-1)

Novo Nordisk announced the Wegovy pill approval on December 22, 2025 (OASIS 4 data), and the FDA approved orforglipron on April 1, 2026 (ATTAIN-1 data).

How much weight do people lose on semaglutide and tirzepatide?

In the trials that led to approval, people lost about 15% of body weight on semaglutide and up to about 21% on high-dose tirzepatide, on average, over roughly 16 to 18 months. Individual results vary.

In STEP 1, average weight change at 68 weeks was 14.9% on semaglutide 2.4 mg versus 2.4% on placebo, as restated in a 2022 follow-up analysis of the trial. In SURMOUNT-1, average reductions were 15.0%, 19.5%, and 20.9% on the 5 mg, 10 mg, and 15 mg doses of tirzepatide. When the FDA approved Zepbound in November 2023, it noted an 18% average reduction at the highest dose in adults without diabetes and 12% in adults with type 2 diabetes.

Is compounded semaglutide still available in Arizona in 2026?

Yes, but within narrower limits than during the shortage years. Compounded semaglutide and tirzepatide are not FDA-approved, and since both shortages ended, the FDA expects them to be compounded only for individual patient needs under federal compounding law, not as mass-produced copies of Wegovy or Zepbound.

The FDA does not review compounded drugs for safety, effectiveness, or quality before they are marketed, but notes that a compounded drug might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug.

Key dates, according to the FDA:

• December 19, 2024: tirzepatide shortage declared resolved. Enforcement discretion ended February 18, 2025 for 503A pharmacies and March 19, 2025 for 503B outsourcing facilities.
• February 21, 2025: semaglutide shortage declared resolved. Enforcement discretion ended April 22, 2025 for 503A pharmacies and May 22, 2025 for 503B facilities.
• February 2026: the FDA announced enforcement against mass-marketed compounded GLP-1s.
• April 30, 2026: the FDA proposed excluding semaglutide, tirzepatide, and liraglutide from the 503B bulks list. As of this writing, the proposal has not been finalized.

The two pharmacy types are regulated differently. Under federal law, 503A pharmacies compound from patient-specific prescriptions under state board of pharmacy oversight, while 503B outsourcing facilities register with the FDA, follow current good manufacturing practice requirements, and are inspected on a risk-based schedule.

Safety concerns are real. As of May 31, 2026, the FDA had received 990 adverse event reports associated with compounded semaglutide and more than 730 with compounded tirzepatide, some requiring hospitalization and possibly related to dosing errors. If you and your provider consider a compounded GLP-1, look for:

• A licensed source. A state-licensed 503A pharmacy or an FDA-registered 503B outsourcing facility, filled on a real prescription.
• Prescriber oversight. A licensed clinician who evaluates you, sets the dose, and follows up.
• No salt forms. The FDA notes that semaglutide sodium and semaglutide acetate are different active ingredients from those in the approved drugs.
• Labs and monitoring. Baseline labs before starting and follow-up as your dose changes.
• Clear dosing instructions. Written directions you fully understand, since the FDA has linked some adverse events to dosing errors.

Do GLP-1 medications cause muscle loss?

Yes, some of the weight lost on GLP-1 medications is lean mass, roughly a quarter to about 40% of the total. Protecting muscle is a core job of a good program, especially after 40.

A 2025 network meta-analysis of 22 randomized trials in Metabolism found lean mass made up approximately 25% of total weight loss with GLP-1 receptor agonists. In a STEP 1 subgroup, 5.3 kg of an average 13.6 kg reduction, or 38%, was lean body mass, as reported in the 2025 joint nutrition advisory.

For women losing muscle and bone around menopause, and men with declining testosterone, this matters.

How much protein should you eat on a GLP-1?

A 2025 joint advisory from the American College of Lifestyle Medicine, American Society for Nutrition, Obesity Medicine Association, and The Obesity Society suggests many people on GLP-1s aim for 1.2 to 1.6 grams of protein per kilogram of body weight per day during active weight loss, or an absolute target of 80 to 120 grams per day.

The advisory also recommends that GLP-1s be prescribed with a structured exercise program: strength training at least three times per week plus at least 150 minutes of moderate aerobic activity weekly. Your target depends on kidney function and goals, and The Obesity Society notes that nutrition support improves adherence.

What should a GLP-1 program include?

A quality GLP-1 program starts with a real medical evaluation, matches the medication to your needs, titrates slowly, protects muscle, and has a plan for maintenance from day one. A prescription alone is not a program.

• A full history. Medications, prior weight-loss attempts, eating patterns, and eating-disorder screening.
• Safety screening. The Zepbound prescribing information lists a personal or family history of medullary thyroid carcinoma or MEN 2 as a contraindication, and advises women on oral contraceptives to switch or add a barrier method for four weeks after starting and after each dose increase.
• Baseline labs. At minimum A1c, fasting glucose, lipids, thyroid, kidney, and liver function. Many people also benefit from a closer look at insulin resistance labs.
• Gradual titration. Dose increases paced to how you tolerate the medication, not a fixed calendar.
• Side-effect management. Help with nausea, constipation, and reflux, and a plan for warning signs.
• Muscle preservation. Protein targets, strength training, and progress tracked over time.
• A maintenance or tapering plan. Decided with you, before you reach your goal.

Red flags include prescribing without a real evaluation or labs, and:

• Claims that a compounded product is the same as, or a generic of, Wegovy or Zepbound
• Guaranteed results or promises of a specific number of pounds
• No discussion of protein, strength training, or what happens when you stop
• No easy way to reach a clinician about side effects

What happens when you stop a GLP-1?

Most people regain much of the weight after stopping. In the STEP 1 extension, participants regained about two-thirds of their lost weight within a year of stopping semaglutide.

In that 2022 analysis, participants lost an average of 17.3% by week 68, regained 11.6 percentage points by week 120, and ended with a net loss of 5.6%. Most improvements in blood pressure and other cardiometabolic markers also moved back toward baseline. NIDDK puts it plainly: you will probably regain some weight after you stop.

That is a reason to plan early with your provider for long-term dosing or a gradual taper.

How much does GLP-1 weight loss cost in Arizona?

Your cost has two parts: the medication and the medical care around it. Brand-name self-pay prices have dropped, and coverage varies by plan.

In December 2025, Lilly lowered self-pay prices for Zepbound vials to $299 to $449 per month depending on dose. Self-pay pricing for the Wegovy pill and Foundayo starts at $149 per month for the lowest dose. Prices change, so confirm when you fill.

About 33.3% of Arizona adults had obesity in 2024, based on CDC Behavioral Risk Factor Surveillance System data.

How does Amsara Health approach GLP-1 weight loss in Arizona?

Amsara Health is a concierge integrative telehealth practice based in Scottsdale, serving adults across Arizona. We treat weight as part of a larger metabolic and hormonal picture, for women and men.

Your first visit is a consultation and full history. Labs are ordered afterward through Sonora Quest or Quest: A1c, fasting glucose, lipids, thyroid, kidney, and liver function, plus a CBC, electrolytes, vitamin D, B12, CRP, cortisol, DHEA, and hormones if appropriate. Your follow-up reviews the results and builds the plan.

If a GLP-1 is appropriate for you, your provider will help you choose among FDA-approved options, including Wegovy, the Wegovy pill, Zepbound, and Foundayo, or compounded semaglutide or tirzepatide when that better fits your needs. Your plan includes protein and strength guidance, a maintenance plan, and tracking of weight, symptoms, and mood between visits.

We prescribe FDA-approved peptide medications. When appropriate, we also prescribe compounded medications from licensed 503A and 503B pharmacies, including GLP-1s and a topical facial cream with GHK-Cu and estradiol. We do not prescribe research-grade peptides, or peptides the FDA has not cleared for compounding, such as BPC-157 or TB-500.

Amsara is direct-pay and does not take commercial insurance, although insurance may still cover prescriptions and some labs. An initial visit is $275 and follow-ups are $175. Membership ($1,999 per year or $799 per quarter) includes free prescription renewal service, 20% off non-insurable tests, priority booking, and weekday provider messaging.

Learn more about care for women, care for men, peptide therapy, and pricing and membership.

Frequently asked questions

Not sure where to start? Book a discovery call to talk it through.

Sources

• Eli Lilly and Company. SURMOUNT-1 results published in The New England Journal of Medicine. Press release, 2022.
• U.S. Food and Drug Administration. FDA Approves New Medication for Chronic Weight Management. FDA, 2023.
• U.S. Food and Drug Administration. Zepbound (tirzepatide) Prescribing Information. FDA, 2023.
• Novo Nordisk. Wegovy pill FDA approval. Company announcement, 2025.
• HCPLive. FDA Approves Semaglutide (Wegovy) Pill as First Oral GLP-1 for Weight Loss. HCPLive, 2025.
• U.S. Food and Drug Administration. FDA Approves First New Molecular Entity Under National Priority Voucher Program. FDA, 2026.
• Eli Lilly and Company. FDA approves Lilly’s Foundayo (orforglipron). Press release, 2026.
• National Institute of Diabetes and Digestive and Kidney Diseases. Prescription Medications to Treat Overweight and Obesity. NIH, 2024.
• U.S. Food and Drug Administration. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize. FDA, updated 2026.
• U.S. Food and Drug Administration. FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List. FDA, 2026.
• U.S. Food and Drug Administration. Compounding Laws and Policies. FDA, updated 2024.
• U.S. Food and Drug Administration. FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. FDA, updated 2026.
• Pharmacy Times. FDA Moves to Restrict Mass-Marketed Compounded GLP-1 Products. Pharmacy Times, 2026.
• Karakasis P, et al. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis. Metabolism, 2025.
• Mozaffarian D, et al. Nutritional priorities to support GLP-1 therapy for obesity: A joint advisory from ACLM, ASN, OMA, and The Obesity Society. Obesity Pillars, 2025.
• The Obesity Society. Nutritional Priorities to Support GLP-1 Therapy for Obesity. TOS, 2025.
• Wilding JPH, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism, 2022.
• PharmExec. Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients. PharmExec, 2025.
• United Health Foundation. Explore Obesity in Arizona (CDC BRFSS data). America’s Health Rankings, 2024.

This article is for educational purposes and is not a substitute for individual medical advice. Talk with a licensed provider about your specific situation.

---

Ready for a metabolic plan built around you?

Unhurried appointments, advanced diagnostics, and a plan built for you.

Already a patient? Visit your Amsara Patient Portal →